ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: BioSpecifics Technologies Corp. (BSTC) Report Updated: Oct 27, 2014 | Print This Page

Get more stock ratings by Louis Navellier

BioSpecifics Technologies Corp. (BSTC)

Rating: Buy Volatility: Conservative
Total Grade: B Industry: Biotechnology
Competitors: UTHR, CMRX, ACHN, MNOV

Stock Analysis

Rating: Monthly View

A
B
C
D
F
October November December January February March April May June July August September

Rating: Weekly View

This Week: B down no change
Last Week: B same no change
Two Weeks Ago: B up no change
service keys

BioSpecifics Technologies Corp.© quotemedia

Company Profile

BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase for various indications. It has a development and license agreement with Auxilium Pharmaceuticals, Inc. for injectable collagenase under the brand XIAFLEX (collagenase clostridium histolyticum) for clinical indications in Dupuytren’s contracture, Peyronie’s disease, and frozen shoulder. The XIAFLEX is under food and drug administration for the treatment of Dupuytren’s contracture; Phase III clinical trials for the treatment of Peyronie’s disease; phase IIb clinical trials for the nonsurgical treatment of Peyronie’s disease; Phase IIa clinical trials for the treatment of frozen shoulder syndrome; Phase II trials for the treatment of human lipoma; and Phase Ib clinical trials to treat cellulite. The company also focuses on the development of collagenase for various other clinical indications, including canine lipoma, as well as keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy indications. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Lynbrook, New York.

Recent News: BioSpecifics Technologies Corp.